Evidence map›Paper›PMID 25676011›Full record

Trial reportClinical and experimental nephrology2015

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.

Kenichi Tanaka, Masaaki Nakayama, Makoto Kanno, Hiroshi Kimura, Kimio Watanabe, Yoshihiro Tani, Yoshimitsu Hayashi, Koichi Asahi, Hiroyuki Terawaki, Tsuyoshi Watanabe

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04017806 (Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation), which is not on this map. Cited by 51 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04017806 unknown statusnot on this mapstarted 2018, after this paper: background citation

Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation

TypeobservationalSponsorTaipei Medical University WanFang HospitalRan2018 to 2020Enrolled60ConditionsArteriovenous Fistula
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenichi TanakaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. kennichi@fmu.ac.jp.
Masaaki NakayamaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Makoto KannoDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Hiroshi KimuraDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kimio WatanabeDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Yoshihiro TaniDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Yoshimitsu HayashiDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Koichi AsahiDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Hiroyuki TerawakiDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Tsuyoshi WatanabeDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression. Febuxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has been reported to have a stronger effect on hyperuricemia than conventional therapy with allopurinol. However, few data are available regarding the clinical effect of febuxostat in patients with CKD.

methodsA prospective, randomized, open-label, parallel-group trial was conducted in hyperuricemic patients with stage 3 CKD. Patients were randomly assigned to treatment with febuxostat (n = 21) or to continue conventional therapy (n = 19). Treatment was continued for 12 weeks. The efficacy of febuxostat was determined by monitoring serum uric acid (UA) levels, blood pressures, renal function, and urinary protein levels. In addition, urinary liver-type fatty acid-binding protein (L-FABP), urinary albumin, urinary beta 2 microglobulin (β2MG), and serum high sensitivity C-reactive protein were measured before and 12 weeks after febuxostat was added to the treatment.

resultsFebuxostat resulted in a significantly greater reduction in serum UA (-2.2 mg/dL) than conventional therapy (-0.3 mg/dL, P < 0.001). Serum creatinine and estimated glomerular filtration rate changed little during the study period in each group. However, treatment with febuxostat for 12 weeks reduced the urinary levels of L-FABP, albumin, and β2MG, whereas the levels of these markers did not change in the control group.

conclusionFebuxostat reduced serum UA levels more effectively than conventional therapy and might have a renoprotective effect in hyperuricemic patients with CKD. Further studies should clarify whether febuxostat prevents the progression of renal disease and improves the prognosis of CKD.

Indexed as

AgedAged, 80 and overAlbuminuriabeta 2-MicroglobulinEnzyme InhibitorsFatty Acid-Binding ProteinsFebuxostatFemaleHumansHyperuricemiaMaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicUric AcidXanthine Oxidasebeta 2-MicroglobulinEnzyme InhibitorsFatty Acid-Binding ProteinsFebuxostatUric AcidXanthine OxidaseChronic kidney disease (CKD)FebuxostatHyperuricemiaUrinary albuminUrinary beta 2 microglobulin (β2MG)Urinary liver-type fatty acid-binding protein (L-FABP)

Identifiers

PMID25676011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.